Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600318791> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2600318791 endingPage "6591" @default.
- W2600318791 startingPage "6591" @default.
- W2600318791 abstract "6591 Background: Rituximab is a chimeric murine/human monoclonal antibody that binds to CD20 on B-lymphocytes. Interleukin-12 (IL-12) facilitates cytolytic T-cell responses and enhances the lytic activity of NK cells. This study was performed to determine the efficacy and toxicity of the combination of IL-12 and rituximab in patients with B-cell non-Hodgkin lymphoma (NHL). Methods: 52 patients with previously treated, histologically confirmed CD20+ low-grade B-cell NHL or mantle cell NHL have been enrolled in this phase 2 study. Patients were randomized to one of two arms: concurrent treatment with rituximab+IL-12 (Arm A) or rituximab with subsequent treatment with IL-12 after documented non-response, defined as less than a partial response (Arm B). Treatment consisted of rituximab 375 mg/m2 on days 1, 8, 15, and 22; and IL-12 300 ng/kg given SQ twice weekly starting on day 2 of cycle 1 for Arm A or upon progression or non-response for Arm B. We focus here on the interim analyses of the first 21 evaluable patients in each arm. Results: To date, 14 of 21 patients on Arm A and 9 of 21 patients on Arm B have discontinued treatment. 8 patients on Arm B have progressed, and have gone on to receive IL-12. On Arm A, 8 patients had grade 3 and 2 patients grade 4 toxicities vs. 2 patients on Arm B with grade 3 toxicities. Of the first 21 evaluable patients accrued to Arm A, 8 responses (38%) have been observed to date. Eight responses (38%) have also been observed on Arm B. All responses observed in Arm B were due to rituximab and none from subsequent treatment with IL-12. Based on these results, accrual to Arm B was closed. However, the subset of mantle cell NHL patients on Arm A had a higher response rate (3/5 patients). As a result, mantle cell NHL patients will continue to be accrued to Arm A. Conclusions: The combination of IL-12 and rituximab was well tolerated. The sequential administration of IL-12 at the time of disease progression after treatment with rituximab did not result in any clinical responses. The concomitant use of IL-12 and rituximab had moderate disease activity in this study; however, promising clinical activity was seen in patients with mantle cell NHL. No significant financial relationships to disclose." @default.
- W2600318791 created "2017-04-07" @default.
- W2600318791 creator A5004152557 @default.
- W2600318791 creator A5007148032 @default.
- W2600318791 creator A5022511085 @default.
- W2600318791 creator A5031537463 @default.
- W2600318791 creator A5036634421 @default.
- W2600318791 creator A5037503098 @default.
- W2600318791 creator A5048644166 @default.
- W2600318791 creator A5059729547 @default.
- W2600318791 creator A5065087784 @default.
- W2600318791 creator A5074099210 @default.
- W2600318791 date "2004-07-15" @default.
- W2600318791 modified "2023-09-24" @default.
- W2600318791 title "NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients" @default.
- W2600318791 doi "https://doi.org/10.1200/jco.2004.22.90140.6591" @default.
- W2600318791 hasPublicationYear "2004" @default.
- W2600318791 type Work @default.
- W2600318791 sameAs 2600318791 @default.
- W2600318791 citedByCount "0" @default.
- W2600318791 crossrefType "journal-article" @default.
- W2600318791 hasAuthorship W2600318791A5004152557 @default.
- W2600318791 hasAuthorship W2600318791A5007148032 @default.
- W2600318791 hasAuthorship W2600318791A5022511085 @default.
- W2600318791 hasAuthorship W2600318791A5031537463 @default.
- W2600318791 hasAuthorship W2600318791A5036634421 @default.
- W2600318791 hasAuthorship W2600318791A5037503098 @default.
- W2600318791 hasAuthorship W2600318791A5048644166 @default.
- W2600318791 hasAuthorship W2600318791A5059729547 @default.
- W2600318791 hasAuthorship W2600318791A5065087784 @default.
- W2600318791 hasAuthorship W2600318791A5074099210 @default.
- W2600318791 hasConcept C126322002 @default.
- W2600318791 hasConcept C141071460 @default.
- W2600318791 hasConcept C143998085 @default.
- W2600318791 hasConcept C18031839 @default.
- W2600318791 hasConcept C203014093 @default.
- W2600318791 hasConcept C2777525834 @default.
- W2600318791 hasConcept C2779338263 @default.
- W2600318791 hasConcept C2779384505 @default.
- W2600318791 hasConcept C2780653079 @default.
- W2600318791 hasConcept C71924100 @default.
- W2600318791 hasConcept C90924648 @default.
- W2600318791 hasConceptScore W2600318791C126322002 @default.
- W2600318791 hasConceptScore W2600318791C141071460 @default.
- W2600318791 hasConceptScore W2600318791C143998085 @default.
- W2600318791 hasConceptScore W2600318791C18031839 @default.
- W2600318791 hasConceptScore W2600318791C203014093 @default.
- W2600318791 hasConceptScore W2600318791C2777525834 @default.
- W2600318791 hasConceptScore W2600318791C2779338263 @default.
- W2600318791 hasConceptScore W2600318791C2779384505 @default.
- W2600318791 hasConceptScore W2600318791C2780653079 @default.
- W2600318791 hasConceptScore W2600318791C71924100 @default.
- W2600318791 hasConceptScore W2600318791C90924648 @default.
- W2600318791 hasIssue "14_suppl" @default.
- W2600318791 hasLocation W26003187911 @default.
- W2600318791 hasOpenAccess W2600318791 @default.
- W2600318791 hasPrimaryLocation W26003187911 @default.
- W2600318791 hasRelatedWork W1999048711 @default.
- W2600318791 hasRelatedWork W2028943076 @default.
- W2600318791 hasRelatedWork W2066388140 @default.
- W2600318791 hasRelatedWork W2132818131 @default.
- W2600318791 hasRelatedWork W2148853365 @default.
- W2600318791 hasRelatedWork W2412433018 @default.
- W2600318791 hasRelatedWork W2462632117 @default.
- W2600318791 hasRelatedWork W2550339062 @default.
- W2600318791 hasRelatedWork W2845298299 @default.
- W2600318791 hasRelatedWork W91236835 @default.
- W2600318791 hasVolume "22" @default.
- W2600318791 isParatext "false" @default.
- W2600318791 isRetracted "false" @default.
- W2600318791 magId "2600318791" @default.
- W2600318791 workType "article" @default.